Dana M. Roque, MD, on Ovarian, Fallopian Tube, and Peritoneal Cancers: Possible New Therapeutic Option for Heavily Pretreated Disease

March 25, 2021 By The ASCO Post Staff

Dana M. Roque, MD, of the University of Maryland Medical Center, discusses phase II results showing that weekly ixabepilone plus biweekly bevacizumab may improve overall response rate as well as progression-free and overall survival for women with platinum-resistant or -refractory ovarian, fallopian tube, and primary peritoneal cancers, a population in need of treatment choices.

Related Content